Here, based on bioinformatics analysis derived from TCGA database and clinical sample validation, we identified that altered tumor mechanics in the TPME and abnormal cellular IDO1 metabolism are two major factors that contribute to ccRCC aggression and compromise treatment efficacy. The gene discussed is IDO1; the disease is neoplasm.